FUJIFILM SONOSITE BV

Their core work

Fujifilm Sonosite is the Dutch arm of the global Fujifilm Sonosite group, a leading manufacturer of point-of-care ultrasound systems. In H2020 projects, they contribute advanced ultrasound and imaging hardware expertise to medical research consortia focused on non-invasive diagnostics and patient monitoring. Their role is providing and adapting portable imaging technology platforms — particularly ultrasound and photoacoustic imaging — for clinical research applications in implant monitoring and cancer detection.

What they specialise in

How they've shifted over time

Their earliest H2020 involvement (2018) split between biomaterial implant monitoring (MgSafe) and cancer diagnostics (EDIT), reflecting broad medical imaging applications. By 2020, their focus narrowed firmly toward cancer-specific imaging, with PRISAR2 exploring watch-and-wait surveillance strategies for rectal cancer using non-invasive imaging. The trajectory shows a clear shift from general biomedical imaging toward oncology-focused diagnostic and monitoring tools.

Moving toward non-invasive cancer monitoring as an alternative to surgical intervention, positioning their ultrasound platforms for oncology surveillance applications.

How they like to work

Fujifilm Sonosite exclusively participates as a partner, never coordinating — consistent with an industry player contributing specialized hardware to research-led consortia. With 44 unique partners across 15 countries from just 3 projects, they join large, diverse consortia (averaging ~15 partners each). Their role is that of a technology provider embedded in academic-clinical networks rather than a project driver.

Despite only 3 projects, they have connected with 44 distinct partners across 15 countries, indicating participation in large pan-European medical research consortia with broad geographic spread.

What sets them apart

As a subsidiary of a major global ultrasound manufacturer, Fujifilm Sonosite brings commercial-grade imaging technology directly into research consortia — something most academic partners cannot offer. They bridge the gap between laboratory imaging research and real clinical deployment, making them valuable for any consortium that needs to move imaging innovations toward actual patient use. Their industry backing also signals a credible path to market for project results.

Highlights from their portfolio

• EDIT
  Largest funding (€681K) and most ambitious scope — combining nanomedicine, photoacoustic, and ultrasound for non-invasive bladder cancer diagnosis and eradication.
• PRISAR2
  Directly addresses the clinical paradigm of cancer watch-and-wait strategies, positioning imaging as an alternative to surgery for rectal cancer patients.